Oxford Biomedica announces CFO transition
Oxford Biomedica announces Chief Financial Officer transition
– Lucinda Crabtree to join as Chief Financial Officer –
Oxford, UK – 17 July 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, “OXB” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Lucinda (Lucy) Crabtree Ph.D. as Chief Financial Officer (CFO) and Board member. Simultaneously, the Company announces that Stuart Paynter will step down as CFO and from the Board after almost seven years of service. These changes will become effective on 2 September 2024 and Stuart will then transition away from Oxford Biomedica following a suitable handover period.
Lucinda Crabtree was previously CFO at MorphoSys AG. As CFO of MorphoSys, Lucy led a finance team across the US and Germany until the closing of the acquisition of the company by Novartis. Prior to MorphoSys, Lucy was CFO at Autolus Therapeutics, a Nasdaq listed clinical stage biopharmaceutical company. Before her time at Autolus, Lucy spent several years as an investment professional at institutions including Woodford Investment Management, Panmure Gordon, Goldman Sachs, J.P. Morgan (originally Bear Stearns) and Jefferies. Lucy also has prior experience as a board observer at several private healthcare companies. She holds a first class Bachelor of Science degree in Physiology and Pharmacology from University College London and a Ph.D. in Pharmacology from University College London.
Dr. Frank Mathias, Chief Executive Officer of Oxford Biomedica, commented: “On behalf of the corporate executive team, I am delighted to welcome Lucy to Oxford Biomedica. Her unique skillset will be immensely valuable to us as we enter the next phase of our growth as a pure-play CDMO. I would also like to warmly thank Stuart for his dedicated service to OXB. Since joining the Company nearly seven years ago, Stuart has been instrumental in its success right the way through to the recent transformation of our business model. We wish him all the best for his future endeavours.”
Stuart Paynter said: “It has been a pleasure and a privilege to help lead Oxford Biomedica through its development to its position as a leading CDMO. The Company is now operationally and financially in stronger health than ever before and, with the transformation complete, it is now the natural time to hand over to someone with Lucy’s skills and experience. I look forward to continuing to support OXB in the interim and then as it enjoys further success and momentum in the future.”
Lucinda Crabtree said: “This is an exciting time to join Oxford Biomedica, having entered a new phase as an international pure-play cell and gene therapy CDMO. I look forward to working with Frank and the senior leadership team alongside the Board, as we continue to execute on this integrated strategy and continue our growth in the backdrop of a rapidly expanding cell and gene therapy market.”
Relevant disclosures
There are no disclosures required to be made in accordance with LR 9.6.13R.
-Ends-
Enquiries:
Oxford Biomedica plc:
Sophia Bolhassan, VP, Corporate Affairs and IR – T: +44 (0) 1865 509 737 / E: ir@oxb.com
ICR Consilium:
T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com
Mary-Jane Elliott / Angela Gray / Davide Salvi
About Oxford Biomedica
Oxford Biomedica (LSE: OXB) is a quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has more than 25 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has bioprocessing and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
